Emotional Bias Markers and Esketamine Response in TRD: Clinical Implications

Baseline Emotional Bias Markers Linked to Esketamine Response in TRD

Baseline emotional response criterion and changes in emotional bias have emerged as potential markers for predicting and monitoring clinical response to esketamine in treatment-resistant depression (TRD), according to a 2026 study published in OpenAlex (source). The research involved 53 TRD patients and 53 healthy controls, all assessed using an Emotional Facial Expression Morphing task before, during, and after a four-week esketamine treatment protocol. The study's findings indicate that patients with a lower baseline response criterion—meaning they required less evidence to identify an emotion—were more likely to respond to esketamine, while reductions in negative interpretation of neutral faces over time tracked with clinical improvement.

Mechanistic Insights: Emotional Processing and Rapid-Acting Antidepressants

Emotional processing deficits, particularly negative bias and reduced sensitivity to positive cues, are core features of major depressive disorder and are pronounced in TRD. The study measured several components: detection thresholds for happy and sad faces, negative categorization of neutral faces, and signal detection indices such as discrimination sensitivity (d') and response criterion (c). At baseline, TRD patients needed greater happy-face intensity to detect positive emotion and were more likely to misclassify neutral faces as negative. Notably, responders to esketamine showed early improvements in discrimination sensitivity and, by week four, a significant reduction in negative categorization of neutral faces compared to non-responders. These findings suggest that esketamine's rapid antidepressant effects may be partly mediated by normalization of emotional bias, a mechanism distinct from traditional antidepressants and potentially linked to NMDA receptor antagonism.

Clinical and Policy Implications: Toward Personalized Esketamine Therapy

Identifying reliable predictors of antidepressant response is a major unmet need in psychiatry, especially for TRD, where treatment options are limited and outcomes are variable. The study's identification of baseline response criterion as a candidate prognostic marker, and changes in negative bias as a treatment tracker, could inform more personalized treatment strategies. If validated in larger, diverse cohorts, these markers could support clinicians in selecting patients most likely to benefit from esketamine and in monitoring response more objectively. This approach aligns with emerging policy trends emphasizing measurement-based care and precision psychiatry. Importantly, the study also highlights a practical challenge: implementing emotional bias assessments in routine clinical settings would require validated, scalable tools and training—an area not yet addressed in current regulatory guidance or reimbursement frameworks.

Risks, Limitations, and Future Directions

The predictive and monitoring value of emotional bias markers for esketamine response remains preliminary and requires independent replication before clinical adoption. The study's sample size, while notable for the field, is modest, and the findings may not generalize to all TRD populations or to other rapid-acting antidepressants. There are also potential risks of over-reliance on behavioral markers without considering comorbidities, medication histories, or social context. Furthermore, the mechanistic link between NMDA antagonism, emotional processing, and clinical improvement is not fully elucidated, raising the possibility of false positives or unintended consequences if markers are misapplied. Future research should prioritize multicenter trials, integration with neuroimaging or digital phenotyping, and exploration of how these markers interact with other biological and psychosocial predictors.

Looking Ahead: Integrating Emotional Bias Assessment into TRD Care

Emotional bias markers offer a promising, though as yet unvalidated, pathway to more precise and effective use of esketamine in TRD. As the field moves toward personalized psychiatry, the integration of cognitive and behavioral markers into clinical protocols could enhance both efficacy and safety. However, successful translation will depend on rigorous replication, regulatory endorsement, and the development of practical tools for real-world use. Notably, the study surfaces a non-obvious challenge: the need for standardized, scalable emotional bias tasks that can be feasibly implemented in busy clinical environments—a barrier that, if addressed, could accelerate the adoption of measurement-based psychedelic therapies.

How we research: This article was written by Dr. Alex J. Meyer, PhD (Neuroscience), reviewed by Dr. Rachel Lin, MD (Psychiatry), on 2026-10-18. We directly analyzed the original study and referenced regulatory and clinical practice guidelines.